scispace - formally typeset
Search or ask a question
Author

Schlachter Stephen T

Other affiliations: Icos, University of Pittsburgh
Bio: Schlachter Stephen T is an academic researcher from Genentech. The author has contributed to research in topics: Protein kinase A & Biological activity. The author has an hindex of 7, co-authored 17 publications receiving 189 citations. Previous affiliations of Schlachter Stephen T include Icos & University of Pittsburgh.

Papers
More filters
Patent
28 Aug 2001
TL;DR: In this article, compounds of Formula (I) that inhibit DNA-dependent protein kinase, compositions comprising the compounds, methods to inhibit the DNA-PK biological activity, and methods to sensitize cells the agents that cause DNA lesions are disclosed.
Abstract: Compounds of Formula (I) that inhibit DNA-dependent protein kinase, compositions comprising the compounds, methods to inhibit the DNA-PK biological activity, methods to sensitize cells the agents that cause DNA lesions, and methods to potentiate cancer treatment are disclosed.

66 citations

Patent
19 Mar 2004
TL;DR: In this article, compositions comprising the compounds, methods of inhibiting the DNA-PK biological activity, and methods of sensitizing cells the agents that cause DNA lesions, and method of potentiating cancer treatment are disclosed.
Abstract: Compound that inhibit DNA-dependent protein kinase, compositions comprising the compounds, methods of inhibiting the DNA-PK biological activity, methods of sensitizing cells the agents that cause DNA lesions, and methods of potentiating cancer treatment are disclosed.

33 citations

Journal ArticleDOI
TL;DR: In reactions with stabilized ylides, γ-lactols of ribo configuration afford 90% Z-olefins and 90% E-olefs as mentioned in this paper.

25 citations

Patent
19 Jan 2006
TL;DR: In this article, compounds of the Formula (I) and diastereomers, tautomers, solvates, metabolites, and pharmaceutically acceptable salts thereof, wherein X, A, L and Y are as defined herein.
Abstract: Disclosed are compounds of the Formula (I) and diastereomers, tautomers, solvates, metabolites, and pharmaceutically acceptable salts thereof, wherein X, A, L and Y are as defined herein. Such compounds are useful in the treatment of immunoregulatory and respiratory diseases in mammals. Also disclosed are methods of using such compounds in the treatment of immunoregulatory and respiratory diseases in mammals and pharmaceutical compositions containing such compounds.

16 citations

Patent
15 Dec 2000
TL;DR: In this paper, the use of the compounds in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, also is disclosed.
Abstract: Novel compounds (II) that are potent and selective inhibitors of PDE4, as well as methods of making the same, are disclosed. Use of the compounds in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, also is disclosed. R?1-R7, R10 and R12? are as in the application.

16 citations


Cited by
More filters
Journal ArticleDOI
19 May 2006-Cell
TL;DR: It is found that p110alpha is the primary insulin-responsive PI3-K in cultured cells, whereas p110beta is dispensable but sets a phenotypic threshold for p110 alpha activity, which illustrates systematic target validation using a matrix of inhibitors that span a protein family.

1,152 citations

Patent
19 Dec 2001
TL;DR: In this article, the pyrazole compounds of formula (IV) were described for protein kinase inhibitors, especially as inhibitors of aurora-2 and GSK-3, for treating diseases such as cancer, diabetes and Alzehimer's disease.
Abstract: This invention describes novel pyrazole compounds of formula (IV) wherein Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; R?x and Ry? are independently selected from T-R3, or taken together with their intervening atoms to form a fused, unsaturated or partially unsaturated, 5-8 membered ring having 1-3 ring heteroatoms selected from oxygen, sulfur, or nitrogen; and R2, R2', and T, and R3 are as described in the specification. The compounds are useful as protein kinase inhibitors, especially as inhibitors of aurora-2 and GSK-3, for treating diseases such as cancer, diabetes and Alzehimer's disease.

470 citations

Patent
14 Mar 2003
TL;DR: In this article, a compound of formula I: or a pharmaceutically acceptable salt or mixtures thereof is presented. And the authors provide a method of utilizing those compounds and compositions in the treatment of various protein kinase mediated disorders.
Abstract: The present invention provides a compound of formula I: or a pharmaceutically acceptable salt or mixtures thereof. These compounds are inhibitors of protein kinases, particularly inhibitors of GSK mammalian protein kinase, and more particularly inhibitors of GSK-3 mammalian protein kinase. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of utilizing those compounds and compositions in the treatment of various protein kinase mediated disorders.

415 citations

Journal ArticleDOI
TL;DR: This work identifies multiplex inhibitors that potently inhibit distinct subsets of PI3-K isoforms, including the first selective inhibitor of p110beta/p110delta, thereby guiding future drug design based on this pharmacophore.

148 citations

Patent
14 Sep 2001
TL;DR: In this article, the triazole compounds of formula (IX) were described for protein kinase inhibitors, especially as inhibitors of GSK-3 and Aurora, for treating diseases such as diabetes, cancer, and Alzheimer's disease.
Abstract: This invention describes novel triazole compounds of formula (IX): wherein Z1 is nitrogen or CR?9 and Z2? is nitrogen or CH, provided that at least one of Z?1 and Z2? is nitrogen; G is Ring C or Ring D; Ring C is selected from a phenyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, or 1,2,4-triazinyl ring, wherein said Ring C has one or two ortho substituents independently selected from -R1; Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; R?x and Ry? are independently selected from T-R?3, or Rx and Ry? are taken together with their intervening atoms to form a fused ring; R1, R3, and T are as described in the specification. The compounds are useful as protein kinase inhibitors, especially as inhibitors of GSK-3 and Aurora, for treating diseases such as diabetes, cancer, and Alzheimer's disease.

107 citations